vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -6.0%). STONERIDGE INC produced more free cash flow last quarter ($2.6M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -7.4%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
AXSM vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $205.2M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 16.2% |
| Operating Margin | -13.8% | -14.4% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | -6.0% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $205.2M | ||
| Q3 25 | $171.0M | $210.3M | ||
| Q2 25 | $150.0M | $228.0M | ||
| Q1 25 | $121.5M | $217.9M | ||
| Q4 24 | $118.8M | $218.2M | ||
| Q3 24 | $104.8M | $213.8M | ||
| Q2 24 | $87.2M | $237.1M | ||
| Q1 24 | $75.0M | $239.2M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-9.4M | ||
| Q2 25 | $-48.0M | $-9.4M | ||
| Q1 25 | $-59.4M | $-7.2M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-7.1M | ||
| Q2 24 | $-79.3M | $2.8M | ||
| Q1 24 | $-68.4M | $-6.1M |
| Q4 25 | — | 16.2% | ||
| Q3 25 | — | 20.3% | ||
| Q2 25 | — | 21.5% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 22.7% | ||
| Q1 24 | — | 20.2% |
| Q4 25 | -13.8% | -14.4% | ||
| Q3 25 | -27.0% | -1.6% | ||
| Q2 25 | -24.5% | -1.1% | ||
| Q1 25 | -46.9% | -1.5% | ||
| Q4 24 | -61.1% | -2.0% | ||
| Q3 24 | -59.8% | 0.1% | ||
| Q2 24 | -89.5% | 1.4% | ||
| Q1 24 | -89.7% | 0.1% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -4.5% | ||
| Q2 25 | -32.0% | -4.1% | ||
| Q1 25 | -48.9% | -3.3% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -3.3% | ||
| Q2 24 | -91.0% | 1.2% | ||
| Q1 24 | -91.1% | -2.6% |
| Q4 25 | $-0.55 | $-2.76 | ||
| Q3 25 | $-0.94 | $-0.34 | ||
| Q2 25 | $-0.97 | $-0.34 | ||
| Q1 25 | $-1.22 | $-0.26 | ||
| Q4 24 | $-1.54 | $-0.22 | ||
| Q3 24 | $-1.34 | $-0.26 | ||
| Q2 24 | $-1.67 | $0.10 | ||
| Q1 24 | $-1.44 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $66.3M |
| Total DebtLower is stronger | — | $180.9M |
| Stockholders' EquityBook value | $88.3M | $179.8M |
| Total Assets | $689.8M | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $66.3M | ||
| Q3 25 | $325.3M | $54.0M | ||
| Q2 25 | $303.0M | $49.8M | ||
| Q1 25 | $300.9M | $79.1M | ||
| Q4 24 | $315.4M | $71.8M | ||
| Q3 24 | $327.3M | $54.1M | ||
| Q2 24 | $315.7M | $42.1M | ||
| Q1 24 | $331.4M | $48.4M |
| Q4 25 | — | $180.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $179.8M | ||
| Q3 25 | $73.7M | $251.2M | ||
| Q2 25 | $73.1M | $260.5M | ||
| Q1 25 | $53.2M | $253.1M | ||
| Q4 24 | $57.0M | $245.3M | ||
| Q3 24 | $92.9M | $271.4M | ||
| Q2 24 | $102.9M | $270.5M | ||
| Q1 24 | $144.0M | $277.3M |
| Q4 25 | $689.8M | $551.2M | ||
| Q3 25 | $669.3M | $632.1M | ||
| Q2 25 | $639.8M | $639.4M | ||
| Q1 25 | $596.7M | $657.4M | ||
| Q4 24 | $568.5M | $621.6M | ||
| Q3 24 | $561.5M | $662.5M | ||
| Q2 24 | $548.2M | $666.7M | ||
| Q1 24 | $545.7M | $675.4M |
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $8.8M |
| Free Cash FlowOCF − Capex | $-18.7M | $2.6M |
| FCF MarginFCF / Revenue | -9.6% | 1.3% |
| Capex IntensityCapex / Revenue | 0.0% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $8.8M | ||
| Q3 25 | $1.0M | $3.6M | ||
| Q2 25 | $-32.4M | $10.7M | ||
| Q1 25 | $-43.4M | $10.9M | ||
| Q4 24 | $-26.2M | $19.2M | ||
| Q3 24 | $-18.6M | $10.8M | ||
| Q2 24 | $-30.1M | $8.7M | ||
| Q1 24 | $-53.5M | $9.1M |
| Q4 25 | $-18.7M | $2.6M | ||
| Q3 25 | $988.0K | $-2.7M | ||
| Q2 25 | $-32.4M | $7.4M | ||
| Q1 25 | $-43.7M | $4.8M | ||
| Q4 24 | $-26.2M | $14.0M | ||
| Q3 24 | $-18.7M | $4.6M | ||
| Q2 24 | $-30.2M | $1.5M | ||
| Q1 24 | $-53.6M | $3.3M |
| Q4 25 | -9.6% | 1.3% | ||
| Q3 25 | 0.6% | -1.3% | ||
| Q2 25 | -21.6% | 3.3% | ||
| Q1 25 | -36.0% | 2.2% | ||
| Q4 24 | -22.1% | 6.4% | ||
| Q3 24 | -17.9% | 2.2% | ||
| Q2 24 | -34.6% | 0.6% | ||
| Q1 24 | -71.4% | 1.4% |
| Q4 25 | 0.0% | 3.0% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.3% | 2.8% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.1% | 2.9% | ||
| Q2 24 | 0.1% | 3.0% | ||
| Q1 24 | 0.1% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
